Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Interleukin-6: a molecule with complex biological impact in cancer

L. Lacina, J. Brábek, V. Král, O. Kodet, K. Smetana,

. 2019 ; 34 (2) : 125-136. [pub] 20180904

Jazyk angličtina Země Španělsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028234

Grantová podpora
16-05534S Grant Agency of the Czech Republic
15-28933A Ministry of Health of the Czech Republic
16-29032A Ministry of Health of the Czech Republic
CZ.1.05/1.1.00/02.0109 BIOCEV
LQ1604 BIOCEV-FAR
NV15-28933A MZ0 CEP - Centrální evidence projektů
NV16-29032A MZ0 CEP - Centrální evidence projektů

Interleukin-6 is a multifaceted cytokine, usually reported as a pro-inflammatory molecule. However, certain anti-inflammatory activities were also attributed to IL-6. The levels of IL-6 in serum as well as in other biological fluids are elevated in an age-dependent manner. Notably, it is consistently reported also as a key feature of the senescence-associated secretory phenotype. In the elderly, this cytokine participates in the initiation of catabolism resulting in, e.g. sarcopenia. It can cross the blood-brain barrier, and so it is in causal association with, e.g. depression, bipolar disorder, schizophrenia, and anorexia. In the cancer patient, IL-6 is produced by cancer and stromal cells and actively participates in their crosstalk. IL-6 supports tumour growth and metastasising in terminal patients, and it significantly engages in cancer cachexia (including anorexia) and depression associated with malignancy. The pharmacological treatment impairing IL-6 signalling represents a potential mechanism of anti-tumour therapy targeting cancer growth, metastatic spread, metabolic deterioration and terminal cachexia in patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028234
003      
CZ-PrNML
005      
20220119150016.0
007      
ta
008      
190813s2019 sp f 000 0|eng||
009      
AR
024    7_
$a 10.14670/HH-18-033 $2 doi
035    __
$a (PubMed)30178819
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sp
100    1_
$a Lacina, Lukáš $u Charles University, First Faculty of Medicine, Institute of Anatomy, Prague, Czech Republic. lukas.lacina@lf1.cuni.cz. Charles University, First Faculty of Medicine, BIOCEV, Vestec, Czech Republic. Charles University, First Faculty of Medicine, Department of Dermatovenereology, Prague, Czech Republic.
245    10
$a Interleukin-6: a molecule with complex biological impact in cancer / $c L. Lacina, J. Brábek, V. Král, O. Kodet, K. Smetana,
520    9_
$a Interleukin-6 is a multifaceted cytokine, usually reported as a pro-inflammatory molecule. However, certain anti-inflammatory activities were also attributed to IL-6. The levels of IL-6 in serum as well as in other biological fluids are elevated in an age-dependent manner. Notably, it is consistently reported also as a key feature of the senescence-associated secretory phenotype. In the elderly, this cytokine participates in the initiation of catabolism resulting in, e.g. sarcopenia. It can cross the blood-brain barrier, and so it is in causal association with, e.g. depression, bipolar disorder, schizophrenia, and anorexia. In the cancer patient, IL-6 is produced by cancer and stromal cells and actively participates in their crosstalk. IL-6 supports tumour growth and metastasising in terminal patients, and it significantly engages in cancer cachexia (including anorexia) and depression associated with malignancy. The pharmacological treatment impairing IL-6 signalling represents a potential mechanism of anti-tumour therapy targeting cancer growth, metastatic spread, metabolic deterioration and terminal cachexia in patients.
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-6 $x fyziologie $7 D015850
650    _2
$a nádory $x imunologie $x metabolismus $7 D009369
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Brábek, Jan, $u Charles University, Faculty of Sciences, Institute of Cell Biology, Vestec, Czech Republic. $d 1973- $7 xx0268678
700    1_
$a Král, Vladimír $u Charles University, First Faculty of Medicine, BIOCEV, Vestec, Czech Republic.
700    1_
$a Kodet, Ondřej $u Charles University, First Faculty of Medicine, BIOCEV, Vestec, Czech Republic. Charles University, First Faculty of Medicine, Department of Dermatovenereology, Prague, Czech Republic. Charles University, First Faculty of Medicine, Institute of Anatomy, Prague, Czech Republic.
700    1_
$a Smetana, Karel $u Charles University, First Faculty of Medicine, BIOCEV, Vestec, Czech Republic. Charles University, First Faculty of Medicine, Institute of Anatomy, Prague, Czech Republic. karel.smetana@lf1.cuni.cz.
773    0_
$w MED00005439 $t Histology and histopathology $x 1699-5848 $g Roč. 34, č. 2 (2019), s. 125-136
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30178819 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20220119150012 $b ABA008
999    __
$a ok $b bmc $g 1433383 $s 1066694
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 34 $c 2 $d 125-136 $e 20180904 $i 1699-5848 $m Histology and histopathology $n Histol Histopathol $x MED00005439
GRA    __
$a 16-05534S $p Grant Agency of the Czech Republic
GRA    __
$a 15-28933A $p Ministry of Health of the Czech Republic
GRA    __
$a 16-29032A $p Ministry of Health of the Czech Republic
GRA    __
$a CZ.1.05/1.1.00/02.0109 $p BIOCEV
GRA    __
$a LQ1604 $p BIOCEV-FAR
GRA    __
$a NV15-28933A $p MZ0
GRA    __
$a NV16-29032A $p MZ0
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace